INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 459s ago
HOUSE PTR37s ago
SEC 13F29s ago
ROBINHOOD CHAIN22s ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Murphy Andrew J reported REGN

Co-Chief Scientific Officer · REGENERON PHARMACEUTICALS, INC. · Common Stock

Side
M
Value
$6.49M
Shares
17.0K
Price
$381.92
Executed
Oct 13, 2026
Disclosed
Oct 15, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 13 executedOct 15, 2026 disclosed

REGN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
16/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+18 / 25

    $6.5M reported value · 35.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · REGN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    MJ
    Murphy Andrew JCo-Chief Scientific Officer
    REGNREGENERON PHARMACEUTICALS, INC.
    Gift
    		G—
    1,054 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    50
    ZY
    Zoghbi Huda YDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$486K
    500 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    57
    ZY
    Zoghbi Huda YDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6.73M
    6,939 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ZY
    Zoghbi Huda YDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,439 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    30
    ZY
    Zoghbi Huda YDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.83M
    7,439 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    42
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$509K
    527 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$4.69M
    12.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Tax withholding
    		F$4.03M
    4,243 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.58M
    2,670 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.43M
    2,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Gift
    		G—
    15 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.29M
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    39
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$194K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    45
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.18M
    1,224 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    53
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6.83M
    7,073 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    42
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$519K
    540 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$4.18M
    4,338 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.47M
    1,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    45
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.01M
    1,040 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001796226-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 13, 2026
    Published
    Oct 15, 2026
    Ingested by INSIDER
    Nov 5, 02:11 UTC
    Last re-read
    Nov 5, 02:11 UTC

    Extracted facts

    Filer
    Murphy Andrew J
    Role
    Co-Chief Scientific Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    REGENERON PHARMACEUTICALS, INC.
    Ticker
    REGN
    Shares
    17.0K
    Price per share
    $381.92
    Value
    $6,492,640
    Execution date (reported)
    Oct 13, 2026
    Owned after transaction
    64.8K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 17.0K
    • Price: $381.92

    = $6,492,640

    What this establishes

    Murphy Andrew J filed this Form 4 reporting a option exercise of REGN on Oct 13, 2026. It became public on Oct 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Co-Chief Scientific Officer
    Murphy Andrew Jcik:0001796226
    Issuer
    REGENERON PHARMACEUTICALS, INC.cik:0000872589

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.